Novo Nordisk Partners with Hims to Sell Obesity Drugs via Telehealth
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy HIMS?
Source: seekingalpha
- Partnership Announcement: Novo Nordisk is set to partner with Hims & Hers Health to sell obesity drugs through its telehealth platform, aiming to enhance patient access to FDA-approved medications for chronic diseases, with an official announcement expected on Monday.
- Market Reaction: Following the report, Novo Nordisk's ADRs rose approximately 2% in after-hours trading, while Hims' stock surged by 40%, indicating a positive market sentiment towards this collaboration.
- Regulatory Challenges: Hims previously saw a partnership collapse due to its refusal to stop selling low-cost compounded versions of Novo's obesity treatment, and recently had to withdraw plans to sell the newly launched Wegovy pill amid regulatory scrutiny, highlighting the complexities of the market environment.
- Legal Dispute: Novo Nordisk has filed a lawsuit against Hims, accusing the company of violating its rights to a key U.S. patent related to semaglutide, which could impact future collaboration prospects.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy HIMS?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on HIMS
Wall Street analysts forecast HIMS stock price to rise
12 Analyst Rating
3 Buy
6 Hold
3 Sell
Hold
Current: 15.880
Low
16.50
Averages
32.95
High
60.00
Current: 15.880
Low
16.50
Averages
32.95
High
60.00
About HIMS
Hims & Hers Health, Inc. provides a consumer-first platform, which helps customers to fulfill their health and wellness needs. Its platform includes access to a provider network, a clinically focused electronic medical record system, digital prescriptions, cloud pharmacy fulfillment, and personalization capabilities. Its digital platform enables access to treatments for a range of chronic conditions, including those related to sexual health, hair loss, dermatology, mental health, and weight loss. It connects patients to licensed healthcare professionals who can prescribe medications when appropriate and prescriptions are fulfilled online through licensed pharmacies on a subscription basis. It also offers access to a range of health and wellness products designed to meet individual needs, which can include curated prescription and non-prescription products. Through its mobile applications, consumers can access a range of educational programs, wellness content, and other services.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Novo Nordisk Partners with Hims to Sell Obesity Drugs via Telehealth
- Partnership Announcement: Novo Nordisk is set to partner with Hims & Hers Health to sell obesity drugs through its telehealth platform, aiming to enhance patient access to FDA-approved medications for chronic diseases, with an official announcement expected on Monday.
- Market Reaction: Following the report, Novo Nordisk's ADRs rose approximately 2% in after-hours trading, while Hims' stock surged by 40%, indicating a positive market sentiment towards this collaboration.
- Regulatory Challenges: Hims previously saw a partnership collapse due to its refusal to stop selling low-cost compounded versions of Novo's obesity treatment, and recently had to withdraw plans to sell the newly launched Wegovy pill amid regulatory scrutiny, highlighting the complexities of the market environment.
- Legal Dispute: Novo Nordisk has filed a lawsuit against Hims, accusing the company of violating its rights to a key U.S. patent related to semaglutide, which could impact future collaboration prospects.
See More
Novo Nordisk Partners with Hims for Weight-Loss Drug Sales
- Partnership Resumption: Novo Nordisk is set to partner with telehealth firm Hims & Hers to sell weight-loss drugs, having previously ended a similar partnership due to Hims's sale of compounded drugs, indicating the company's adaptability in the market.
- Positive Market Reaction: Novo Nordisk's shares rose over 2% in after-hours trading, while Hims surged nearly 40%, reflecting optimistic market expectations for this partnership, which could enhance both companies' competitiveness in the weight-loss drug sector.
- Growing Market Demand: By 2030, approximately 25 million Americans are expected to use GLP-1 weight-loss drugs, with J.P. Morgan projecting this market to become one of the fastest-growing in healthcare, suggesting significant opportunities for Novo and Hims's collaboration.
- Legal Dispute Context: Despite ongoing patent infringement litigation between Novo and Hims, the decision to resume partnership highlights the company's balancing act between legal risks and market opportunities, which may influence future strategic decisions.
See More
Novo Nordisk and Hims End Feud, Announce Partnership
- Partnership Restoration: Novo Nordisk has decided to sell its weight-loss drug on Hims' telehealth platform, ending their public feud, with an official announcement expected on Monday, indicating a strategic shift in both companies' market approaches.
- Legal Dispute Context: Last month, Novo Nordisk sued Hims for marketing a compounded version of its new weight-loss pill, alleging patent violations related to the ingredient in Wegovy, highlighting the pharmaceutical industry's strong emphasis on intellectual property rights.
- Intensifying Market Competition: The weight-loss drug market is facing increased competition due to recent supply shortages, with the FDA planning to enhance scrutiny of copycat weight-loss drugs, potentially reshaping market dynamics and prompting companies to reassess their product strategies.
- Significant Stock Price Fluctuations: Hims' stock surged 39.77% to $22 in after-hours trading, while Novo Nordisk's stock rose 2.12% to $39.40, reflecting the market's positive response to the new partnership and investor interest in the weight-loss drug market outlook.
See More
Supreme Court Overturns Trump's Tariffs, Economic Implications Ahead
- Tariff Policy Change: The U.S. Supreme Court has overturned Trump's tariffs, affecting approximately $170 billion in tariffs; while some tariffs are lifted, the compensation issue remains unresolved, impacting cost structures and future profitability for affected companies.
- Economic Growth Slowdown: The latest GDP growth rate stands at 1.4%, below expectations, with consumer spending growth decelerating from 3.5% to 2.4%, indicating fragility in economic recovery that may lead to cautious corporate investment and expansion decisions.
- Inflationary Pressures: The core inflation rate has risen by 3% year-over-year, exceeding market expectations; although the market's initial reaction was muted, persistent high inflation could undermine consumer confidence and spending, posing risks to economic growth.
- Retail Market Dynamics: Walmart's earnings report indicates that high-income consumers continue to spend, while lower-income groups are cutting back due to rising costs, reflecting economic imbalances that may prompt retailers to adjust pricing strategies and market approaches.
See More
JPMorgan Significantly Reduces Stake in Hims & Hers Health
- Stake Reduction: JPMorgan Chase & Co.'s recent regulatory filing reveals a drastic reduction in its holdings of Hims & Hers to approximately 3.88 million shares, down from 17.8 million in September 2025, reducing its ownership stake to 1.7%, indicating a loss of confidence in the company.
- Regulatory Pressure: Hims faces increasing scrutiny as the FDA issued warning letters to 30 telehealth companies, including Hims, regarding misleading marketing of compounded weight-loss drugs, particularly its $49 compounded pill, which could adversely affect market performance and investor sentiment.
- Market Reaction: Despite Hims' stock falling over 3% to $15.88 on Thursday, it rose nearly 1% in early premarket trading on Friday, reflecting a mixed market sentiment towards the company's future potential, although overall sentiment remains bearish.
- Investor Focus on New Areas: Amid regulatory challenges for GLP-1 drugs, investors are turning their attention to peptides as a potential growth driver, with the CEO of Futurum Group suggesting that Hims could be the most viable public company for scaling peptide production, potentially offsetting any downside related to GLP-1 drugs.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
Novo Nordisk Partners with Hims to Sell Obesity Drugs via Telehealth
- Partnership Announcement: Novo Nordisk is set to partner with Hims & Hers Health to sell obesity drugs through its telehealth platform, aiming to enhance patient access to FDA-approved medications for chronic diseases, with an official announcement expected on Monday.
- Market Reaction: Following the report, Novo Nordisk's ADRs rose approximately 2% in after-hours trading, while Hims' stock surged by 40%, indicating a positive market sentiment towards this collaboration.
- Regulatory Challenges: Hims previously saw a partnership collapse due to its refusal to stop selling low-cost compounded versions of Novo's obesity treatment, and recently had to withdraw plans to sell the newly launched Wegovy pill amid regulatory scrutiny, highlighting the complexities of the market environment.
- Legal Dispute: Novo Nordisk has filed a lawsuit against Hims, accusing the company of violating its rights to a key U.S. patent related to semaglutide, which could impact future collaboration prospects.
See More
Novo Nordisk Partners with Hims for Weight-Loss Drug Sales
- Partnership Resumption: Novo Nordisk is set to partner with telehealth firm Hims & Hers to sell weight-loss drugs, having previously ended a similar partnership due to Hims's sale of compounded drugs, indicating the company's adaptability in the market.
- Positive Market Reaction: Novo Nordisk's shares rose over 2% in after-hours trading, while Hims surged nearly 40%, reflecting optimistic market expectations for this partnership, which could enhance both companies' competitiveness in the weight-loss drug sector.
- Growing Market Demand: By 2030, approximately 25 million Americans are expected to use GLP-1 weight-loss drugs, with J.P. Morgan projecting this market to become one of the fastest-growing in healthcare, suggesting significant opportunities for Novo and Hims's collaboration.
- Legal Dispute Context: Despite ongoing patent infringement litigation between Novo and Hims, the decision to resume partnership highlights the company's balancing act between legal risks and market opportunities, which may influence future strategic decisions.
See More
Novo Nordisk and Hims End Feud, Announce Partnership
- Partnership Restoration: Novo Nordisk has decided to sell its weight-loss drug on Hims' telehealth platform, ending their public feud, with an official announcement expected on Monday, indicating a strategic shift in both companies' market approaches.
- Legal Dispute Context: Last month, Novo Nordisk sued Hims for marketing a compounded version of its new weight-loss pill, alleging patent violations related to the ingredient in Wegovy, highlighting the pharmaceutical industry's strong emphasis on intellectual property rights.
- Intensifying Market Competition: The weight-loss drug market is facing increased competition due to recent supply shortages, with the FDA planning to enhance scrutiny of copycat weight-loss drugs, potentially reshaping market dynamics and prompting companies to reassess their product strategies.
- Significant Stock Price Fluctuations: Hims' stock surged 39.77% to $22 in after-hours trading, while Novo Nordisk's stock rose 2.12% to $39.40, reflecting the market's positive response to the new partnership and investor interest in the weight-loss drug market outlook.
See More
Supreme Court Overturns Trump's Tariffs, Economic Implications Ahead
- Tariff Policy Change: The U.S. Supreme Court has overturned Trump's tariffs, affecting approximately $170 billion in tariffs; while some tariffs are lifted, the compensation issue remains unresolved, impacting cost structures and future profitability for affected companies.
- Economic Growth Slowdown: The latest GDP growth rate stands at 1.4%, below expectations, with consumer spending growth decelerating from 3.5% to 2.4%, indicating fragility in economic recovery that may lead to cautious corporate investment and expansion decisions.
- Inflationary Pressures: The core inflation rate has risen by 3% year-over-year, exceeding market expectations; although the market's initial reaction was muted, persistent high inflation could undermine consumer confidence and spending, posing risks to economic growth.
- Retail Market Dynamics: Walmart's earnings report indicates that high-income consumers continue to spend, while lower-income groups are cutting back due to rising costs, reflecting economic imbalances that may prompt retailers to adjust pricing strategies and market approaches.
See More
JPMorgan Significantly Reduces Stake in Hims & Hers Health
- Stake Reduction: JPMorgan Chase & Co.'s recent regulatory filing reveals a drastic reduction in its holdings of Hims & Hers to approximately 3.88 million shares, down from 17.8 million in September 2025, reducing its ownership stake to 1.7%, indicating a loss of confidence in the company.
- Regulatory Pressure: Hims faces increasing scrutiny as the FDA issued warning letters to 30 telehealth companies, including Hims, regarding misleading marketing of compounded weight-loss drugs, particularly its $49 compounded pill, which could adversely affect market performance and investor sentiment.
- Market Reaction: Despite Hims' stock falling over 3% to $15.88 on Thursday, it rose nearly 1% in early premarket trading on Friday, reflecting a mixed market sentiment towards the company's future potential, although overall sentiment remains bearish.
- Investor Focus on New Areas: Amid regulatory challenges for GLP-1 drugs, investors are turning their attention to peptides as a potential growth driver, with the CEO of Futurum Group suggesting that Hims could be the most viable public company for scaling peptide production, potentially offsetting any downside related to GLP-1 drugs.
See More
Health Care Stocks Decline, NYSE Health Care Index Drops 2.3%
- Overall Decline in Health Care Stocks: On Thursday afternoon, health care stocks broadly fell, with the NYSE Health Care Index dropping 2.3%, reflecting market concerns about the sector's outlook, which could impact investor confidence and lead to capital outflows.
- Diminished Market Sentiment: The downward trend in the health care sector may be linked to overall economic uncertainty, as investors grow increasingly wary of potential policy changes and regulatory pressures, thereby affecting stock performance.
- Investor Reactions: In light of the decline in health care stocks, investors may reassess their portfolios, seeking more defensive asset allocations to mitigate potential market volatility and risks.
- Uncertain Industry Outlook: The short-term performance of the health care sector may be influenced by multiple factors, including policy changes and fluctuations in market demand, prompting investors to closely monitor developments to adjust their investment strategies.
See More
